| Success story

Engimmune Therapeutics

Engineering the next-generation of T cell receptor therapies against cancer

Engimmune is a spinout from Prof. Sai Reddy’s research group at the Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zürich in Basel. Built on foundational technologies developed by Rodrigo Vazquez-Lombardi and Sai Reddy, Engimmune was founded in August 2021 by Rodrigo Vazquez-Lombardi, its current CSO, Sai Reddy and Søren Mouritsen, the company’s CEO.  

Engimmune is a platform technology and product company engineering highly potent and specific immunotherapies based on T-cell receptor (TCR) targeting of cancer. By applying genome editing, deep sequencing, functional screening and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-based therapies.  

BaseLaunch has supported Engimmune since early 2021 and helped the company take the first steps outside of academia, providing initial financing, strategic advice and access to its biotech network. BaseLaunch introduced to the team Søren Mouritsen, an experienced biotech entrepreneur, now Engimmune’s CEO. The strong management team and the excellent science behind Engimmune’s groundbreaking technologies were pivotal to the rapid progress of the company, culminating with the completion of a $16.7M seed financing, co-led by Pureos Bioventures and Novo Holdings 

BaseLaunch has supported Engimmune from before our formation through to the current financing. Their financing and guidance was invaluable to help us build the company and team, and key to fast-track our fundraising.

Prof. Dr. Sai ReddyCo-Founder, Scientific Advisor & Associate Professor at ETH Zurich in the Department of Biosystems Science & Engineering (D- BSSE, Basel, Switzerland)

Application cycle is now open!

The next deadline for 2022 is September 1st.